Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 28,200 shares, a growth of 24.2% from the February 13th total of 22,700 shares. Based on an average trading volume of 106,200 shares, the short-interest ratio is currently 0.3 days. Approximately 7.4% of the shares of the stock are short sold.

Exicure Stock Down 3.0 %

Shares of Exicure stock opened at $12.83 on Monday. The firm has a market cap of $33.43 million, a PE ratio of -6.20 and a beta of 3.84. The business has a 50-day moving average price of $10.28 and a 200 day moving average price of $9.24. Exicure has a twelve month low of $1.44 and a twelve month high of $36.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC purchased a new position in Exicure, Inc. (NASDAQ:XCUR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 42.82% of the company’s stock.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.